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Abstract In human serum we found strong defensin binding to the complexes of activated Cl complement (CT) and Cl inhibitor (Cli). Purified 
Clq, activated Cl tetrame_r (T&) and Cli did not bind defensin. When f& was dissociated by EDTA, only the activated Cls (Cls) bound defensin. 
Binding of defensins to Cl complement represents a newly recognized bridge between the complement- and phagocyte-mediated host defenses, and 
a potential mechanism for protecting infected tissue from cytotoxic injury by defensin. 
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1. Introduction 
Human defensins or human neutrophil peptides, HNP, are 
variably cationic, 3.5 kDa antimicrobial, cytotoxic and pro- 
inflammatory peptides, containing six disulfide-paired cys- 
teines. Defensins are abundant in human neutrophils and small 
intestinal Paneth cells [l]. Neutrophil activation leads to the 
secretion of up to 10% of their defensin content [2], accounting 
for the defensin concentrations over 100 pg/ml in the plasma 
of some septic patients [3]. Unless inactivated, extracellular 
defensins may injure host tissues [l]. What mechanisms prevent 
defensin cytotoxicity? Previously we documented defensin 
binding to methylamine-activated ‘fast’ a2-macroglobulin 
(a2M) in human plasma [4]. In this study, we describe defensin 
binding to Cl complement. 
C 1 complement is a calcium-dependent multimolecular com- 
plex that initiates the classical pathway of complement activa- 
tion [5]. Cl is composed of one recognition subunit, Clq and 
one tetrameric protease subunit abbreviated as r,s,. Binding of 
aggregated IgG and other stimuli to Cl leads to autocatalyzed 
cleavage of its subcomponent proenzyme Clr to active protease 
Cir (the bar above indicates an active enzyme). Cir in turn 
cleaves and activates proenzyme Cls into protease Cis. The 
resulting proteolytically active form of Cl (CT) is regulated by 
Cl inhibitor (Cli) [S], a protein belonging to the serine protease 
inhibitor (serpins) superfamily [6]. Cli binds to Ci and dissoci- 
ates the Ci multimer. When only Clr is activated, Cli releases 
two molecules of Cli-Cir-Cls [7]. When both Clr and Cls are 
activated, two molecules of C 1 i-Cir-Cis-C 1 i are released [8]. 
In the current paper we identify defensin-binding Cl forms. 
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2. Materials and methods 
2.1. Reagents and materials 
Human defensin HNP-1 and pig neutrophil peptide protegrin, PG-1, 
were isolated from human and pig neutrophils [9,10]. Tachyplesin, 
TP-1, was purchased from Bachem (King of Prussia, PA). Human Cl 
subcomponents were isolated by IgG-Sepharose and DEAE chroma- 
tography [11], Cli was purified by the method of Sim and Reboul[l2]. 
Goat anti-Clq, -Clr, -Cls and -Cli IgG were purchased from Atlantic 
Antibodies (Scarborough, ME). Control goat IgG and human serum 
albumin (HSA) were from Sigma (St. Louis, MO). Rabbit anti-goat 
IgG alkaline phosphatase conjugate was from Bio-Rad (Richmond, 
CA). Iodobead and Iodo-gen iodination reagents were supplied by 
Pierce (Rockford, IL). Sodium iodide-125 was purchased from Du- 
Pont-NEN (Boston, MA). BioBlot nitrocellulose (NC) membranes, 
0.45 mM pore size, were from Costar (Cambridge, MA). 
Blood was obtained from volunteer blood donors, and used to pre- 
pare normal human serum (NHS), or normal human plasma (NHP) 
containing 5 mM EDTA. To minimize the in vitro discharge of cellular 
constituents into serum or plasma, the blood cells were immediately 
removed by centrifugation [4]. 
2.2. Detection of defensin binding in human blood 
HNP-1, PG-1 and TP-1 were iodinated by the Iodo-gen or Iodobeads 
method [13] to a specific activity of 10 &i@g. Trace amounts of 
radiolabeled HNP-1, PG-1 or TP-1 was incubated with NHS, NHP, 
and purified Cl subcomponents for 30 min at 37’C. Resulting com- 
plexes were followed by native or rate PAGE at pH 5.7 [14] or at pH 
8.8 [15]. After electrophoresis toward the anode in a Minigel apparatus 
(Hoeffer Scientific Instruments, San Francisco, CA) at 4”C, gels were 
Coomassie stained, dried and exposed to X-OMAT AR films (Eastman 
Kodak Co., Rochester, NY) at -70°C for l-3 days. 
2.3. Immunoprecipitation 
Goat IgG to Cl subcomponents, or control IgG were diluted in 20 
mM Tris-HCl, 150 mM NaCl, pH 7.5 (T’BS) and incubated for 1 h at 
room temperature with equivalent volumes of NHS + EDTA. Samples 
were further incubated with trace amounts of radiolabeled HNP-1 
([“-?]HNP) for 30 min at 37“C and directly subjected to 5% native 
PAGE, pH 8.8, and autoradiography. Resulting autoradiograms were 
analyzed using the Speedlight gel documentation system (BfI Sci Tech, 
Carlsbad, CA) and Qgel software (Kendrick Lab. Inc., Madison, WI). 
2.4. Immunoblotting 
Samples containing radiolabeled defensin in NHS or 
NHS + aggregated IgG (NHS + aggr IgG) were used for 5% native 
PAGE, pH 8.8. To ‘activate’ NHS, human IgG, 30 mg/ml in TBS was 
aggregated at 56°C for 30 min, and 10 ~1 of this solution was added 
to 50 ~1 of NHS for 30 min at 37°C. Half of each sample of NHS and 
NHS + aggr IgG was incubated with 10 mM EDTA for 30 min on ice 
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to chelate Ca*‘. Following PAGE, the gels were lectrotransferred onto 
NC in 25 mM Tris-HCl, 192 mM glycine buffer, pH 8.2, 10% methanol 
for 1 h at a constant current 250 mA. The same NC membranes were 
first used for autoradiography and then for immunoblotting with goat 
anti-Clq, -Cli, -Clr, -Cls or control IgG [4]. 
3. Results 
3.1. Defensin binding in human blood is calcium-dependent 
Defensin interactions with a2M [4] could not explain the 
complex pattern of defensin binding in human blood. In a 
search for the additional defensin-binding proteins we noticed 
that defensin binding depended on the presence of Ca”. 
Chelating of Ca” with EDTA resulted in the shift of defensin 
binding (Fig. 1). The effect of EDTA was reversed by excess 
Ca2+. Excess Ca” by itself did not change defensin binding in 
NHS. Since native PAGE, represented in Fig. 1 and the follow- 
ing figures, separates anionic plasma proteins according both 
to their molecular weight and charge, we used purified ‘slow’ 
and ‘fast’ a2M, transferrin, HSA, Cl subcomponents 
and Coomassie staining to ‘calibrate’ the gels in each experiment. 
Unbound, cationic defensin did not enter the native gels [3]. 
tX2M- 
Tf- 
3.2. IdentiJcation of defensin-binding Cl forms 
Based on the Ca”-dependence, we suspected that defensin 
may interact with Cl complement, since (i) coagulation and 
complement multienzyme cascades are the two major Ca’+- 
dependent systems in blood, (ii) in the absence of calcium, Cl 
complement breaks into the individual subcomponents, and 
(iii) during native PAGE the Cls subcomponent migrates in the 
a2 region adjacent to transferrin [16]. 
Fig. 1. The effect of calcium on defensin binding in normal human 
serum. An autoradiogram after 10% native PAGl?, pH 5.7. Each lane 
containes 1.5 ul of NHS and 0.5 nrr of I’*‘IlHNP. As indicated. NHS 
was preincubated with 5 mM and/& 1dmM Ca” for 30 min at 4°C. 
Lines labeled a2M and Tf mark the positions of ‘slow’ u2M and trans- 
ferrin on the Coomassie stained gel. The bar on the right indicates the 
defensin-binding zone in NHS + EDTA. 
Preliminary immunoprecipitation experiments uggested e- 
fensin binding to Ci-Cli complexes, containing Cis, Cir and 
Cli in NHS, and to Cir-Cli dimers and monomeric Cls in 
NHS + EDTA (not shown). Ci-Cli interactions in NHS are 
known to result in the formation of the Cli-Cir-Cls and 
Cli-Cir-Cis-Cli complexes [7,8]. The first complex increases 
in NHS after prolonged incubation at 37’C, and the second 
appears after activation with aggregated IgG [7]. To identify 
composition of defensin-binding Cl-Cli complexes, we com- 
pared defensin redistribution in NHS and NHS + aggr IgG. 
Alignment of defensin-containing bands on autoradiograms 
with the bands stained by anti-Cl antibodies on the im- 
munoblots allowed us to demonstrate defensin binding to Cli- 
Cir-Cls in non-activated NHS, and to both Cli-Cir-Cls and 
Cli-CirCis-Cli in NHS + aggr IgG (Fig. 2A). Immunoblot- 
ting identified defensin interaction with Cis-Cli as well as 
Cir-Cli in NHS + aggr IgG + EDTA and Cls and Cir-Cli in 
NHS + EDTA (Fig. 2B). Defensin bound only to the more 
anionic (lower) Cls band, present in NHS + EDTA (Fig. 2B, 
lanes aCls), but not in NHS (Fig. 2A, lanes aCls). Since the 
cationic Clq subunit did not enter the native gels, immunoblots 
probed with anti-Clq antibodies yielded the same background 
staining as non-immune goat IgG (not shown). 
F2E2 activation (Fig. 3). When EDTA was added to ?& + Cli, 
defensin binding shifted into the lower molecular weight zone 
of Cir-Cli and Cis-Cli dimers. The addition of EDTA to Y,?, 
resulted in defensin binding to monomeric Cis, and subsequent 
addition of Cli moved defensin binding up to Cir-Cli and 
Cis-Cli and to some extent to Cli-Cir-Cis-Cli. In general, 
the radioactive bands that resulted from defensin binding to 
individual products of ?Zi2 interaction with Cli and EDTA 
aligned very well with defensin-binding bands in NHS, 
NHS + EDTA and NHS + aggr IgG (Fig. 3). Defensin did not 
bind to F2Z2 in the absence of Cli, and did not bind to purified 
Cli and Clq (not_shown),Although defensin bound equally 
well to purified Cls and Cls-Cli complexes, defensin did not 
bind to purified Cir, unless it was reacted with Cli (not shown). 
Table 1 
Forms of Cl and their defensin binding 
Cl form Form present in Form present in Defensin 
serum serum + EDTA binding 
3.3. Defensin interactions with purt$ed Cl tetramer 
Clr 
Cls 
Clq 
- 
To confirm defensin interactions with Cl, we used purified 
Cl tetramer 2s2, which was 90-95% activated as was shown by 
it dissociation into heavy and light chains in SDS-PAGE under 
reducing conditions [5]. Preincubation of rZ$ with an excess of 
Cli resulted in defensin binding to Cli-Clr-Cis-Cli and to a 
lesser extent, to Cli-Cir-Cls, corresponding to the degree of 
Cl tetramer 2s2 - 
Cl + 
Cli + 
Cir-C 1 i
Cis-C I i 
Cli-Ci-Cls Y 
C 1 i-Cir-cis-c 1 i + 
+ - 
+ + 
+ 
- 
- 
+ 
+ + 
+ + 
- + 
- + 
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Fig. 2. Identification of defensin-<=l complexes in NHS (A) and NHS + EDTA (B). Comparision of autoradiograrns and corresponding irnmunoblots 
after 5% native PAGE, pH 8.8. Each lane contains 2ng of [‘251JHNP and 1.5 ~1 of NHS + aggr IgG + EDTA. Anti-Cl goat IgG (ccclq, aCli, aClr, 
aCls) were incubated with NC strips, containing NHS (a) and NHS + aggr IgG (b), or NHS + EDTA (c) and NHS + aggr IgG + EDTA (d). The 
line labeled a2M marks the positions of ‘slow’ a2M on the Coomassie stained gel. Arrows on the left indicate defensin-binding proteins on 
autoradiograms, identified by inununoblotting (labeled arrows onthe right). 
3.4. Cl complement also binds non-defensin cationic peptides 
As illustrated on Fig. 4, PG-1 and TP-1, small cationic pep- 
tides from pig neutrophils [lo] and horseshoe crab amebocytes 
[17], also bound to Cli-CirCls in NHS. While defensin, in 
addition to CliXir-Cls, interacted with ‘slow’ and ‘fast’ a2M, 
CliCir-Cls was the main PG-l-binding protein in NHS. 
There was little binding of PG-1 and TP-1 to ‘fast’ or ‘slow’ a2M. 
4. Discussion 
We found defensin interactions with Cl complement and 
identified defensin-binding Cl forms (Table 1). Inactivation of 
Ci by C li was necessary for the binding. The interaction of C 1 i
with Ci complement is known to change its calcium-binding 
properties and antigenicity [5,18]. It is likely that Cli interac- 
tions with Ci also ‘opens’ defensin-binding sites. In additional 
experiments we found defensin binding to the purified N-termi- 
nal a-fragment of Cls (not shown). We did not see defensin 
binding to the more cationic (higher) Cls band in 
NHS + EDTA (Fig. 2B, lanes aCls), which appears as a result 
of proteolytic cleavage of the N-terminal part of the heavy 
chain of Cls [ 191. Since the a-fragment of Cls participates in 
calcium-dependent formation of Cl tetramer and whole Cl 
molecule [20], its defensin binding site(s) are likely to be 
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Fig. 3. Defensin interactions with purified Ci tetramer. An autoradiogram after 5% native PAGE, pH 8.8. Samples contain 0.5 ng of [“‘IJHNP added 
to 1.5 ~1 of NHS f aggr IgG f EDTA or 4 pug of I& + 6pg Cli f EDTA. The line labeled a2M marks the positions of ‘slow’ a2M on the Coomassie 
stained gel. Arrows indicate defensin-binding Cl forms. 
masked. This may explain why we did not observe defensin 
binding to purified ?&, or Ci complement reconstituted from 
purified Y& and C 1 q. 
NHS 
S-a2M 
F-a2M 
Cli-ClECls 
Fig. 4. Binding of protegrin and tachyplesin to Ci complement. An 
autoradiogram after 5% native PAGE, pH 8.8. As indicated, samples 
contain 0.5 ng of [‘z51]HNP, 4 ng of [‘251]PG-1 or [‘*‘I]TP-1 in 1.5 ~1 of 
NHS. Lines labeled S-a2M and F-a2M mark the positions of ‘slow’ and 
‘fast’ a2M on the Coomassie stained gel. Arrow indicates the position 
of Cli-Ci;-Cls complex in NHS. 
Cl concentration in human blood approximates to 180 nM, 
and up to 5% of Ci is inactivated [2 11, yielding 18 nM of CT-C 1 i
complexes. Assuming one binding site per complex, inactivated 
Ci will bind 18-36 nM (60-120 ng/ml) of extracellular defen- 
sins. In normal human plasma we measured median defensin 
concentrations of 25 ng/ml[3]. Ci-Cli complexes can thus bind 
and dispose of defensins at their physiological evel. Indeed, in 
our experiment with NHS and NHP and close to physiological 
amounts of defensin (Figs. 3 and 4), Cl forms, along with a2M, 
were the main defensin-binding compartments. At the high 
level found in the plasma of septic patients, defensins may 
chiefly bind to and be disposed of by a2M [3] the concentration 
of which in human blood (24 PM) is much higher than that 
of Cl complement [22]. Human serum albumin, the major ani- 
onic protein of human blood, did not compete with defensin 
binding to purified Cl subcomponents even when HSA was 
added in 100 fold excess, nor did HSA compete with defensin 
binding to Ci in NHS or NHP (not shown). 
Cationic peptides PG- 1 and TP- 1 also interact strongly with 
Ci-Cli complexes in NHS. Defensins, protegrins and 
tachyplesins constitute structurally distinct families of cysteine- 
rich antimicrobial peptides. Protegrins, discovered and charac- 
terized recently [lo], have a molecular weight of approximately 
2 kDa and contain four cysteine residues that form two intra- 
molecular cysteine disulfide bonds. Tachyplesins resemble PG 
in molecular weight and amount of cysteine residues but have 
different primary structures and cysteine placement. Although 
defensins are almost twice as large as PG or TP and have six 
cysteine residues, they share some N-terminal similarities with 
protegrins [lo]. The natural diversity of cysteine-rich antimicro- 
bial peptides may be used to identify defensin site(s) involved 
in CT binding. 
The uptake of HNP-Cis-Cli complexes in our preliminary 
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experiment with human hepatoma cell line HepG2 (not shown) 
suggests that binding to Ci could serve as a disposal or 
recycling pathway for defensins through the SEC receptors, 
responsible for the uptake of serpin-protease complexes [23]. 
Complement and phagocytes are the major interlinked systems 
of innate host defense. The current study suggests that acti- 
vated complement may also serve to bind defensins released 
extracellularly during neutrophil activation. This mechanism 
may confine the activity of defensins to the phagolysosome, and 
may protect the surrounding tissue from cytotoxic damage. 
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